Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.51 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11846412 | 0.92 | L3MBTL1 (0.54) | SMN1; SMN2ALDH1A1ATMMAPTL3MBTL1 | |
| SCHEMBL11841446 | 0.87 | SMN1; SMN2 (0.48) | SMN1; SMN2ALDH1A1ATMPOLBGAA | |
| SCHEMBL10426938 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1ATMPOLBGAA | |
| SCHEMBL9795030 | 0.86 | TSHR (0.49) | SMN1; SMN2ALDH1A1TSHRATML3MBTL1 | |
| SCHEMBL10426881 | 0.86 | SMN1; SMN2 (0.47) | SMN1; SMN2ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL16088846 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2ALDH1A1TSHRATMPOLB | |
| SCHEMBL9795024 | 0.85 | ALDH1A1 (0.56) | SMN1; SMN2ALDH1A1TSHRGAAMEN1 | |
| SCHEMBL10900620 | 0.85 | SMN1; SMN2 (0.59) | SMN1; SMN2ALDH1A1TSHRATMPOLB | |
| SCHEMBL1665202 | 0.84 | SMN1; SMN2 (0.70) | SMN1; SMN2ALDH1A1TSHRATMPOLB | |
| SCHEMBL10426889 | 0.84 | CHRNB2 (0.51) | SMN1; SMN2ALDH1A1PKMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106324794-A | Chip automatic focusing apparatus of gene spectrum sequencing device and focusing method thereof | 徐州工程学院 | 2017-01-11 | — | — | CN | claimed |
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | claimed |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | NAVINTA LLC. | 2008-05-29 | — | — | US | claimed |
| EP-4662202-A1 | PYRIDINE AND DIHYDROPYRIDINE COMPOUNDS AND USES THEREOF | Clark Atlanta University, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| CN-222488915-U | Acetoacetic acid (N-benzyl-N-methyl) amino ethyl ester rectifying device | 大连万福制药有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024167861-A1 | PYRIDINE AND DIHYDROPYRIDINE COMPOUNDS AND USES THEREOF | CLARK ATLANTA UNIVERSITY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| CN-106324794-A | Chip automatic focusing apparatus of gene spectrum sequencing device and focusing method thereof | 徐州工程学院 | 2017-01-11 | — | — | CN | disclosed |
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-7585978-B2 | Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions | NAVINTA LLC (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | NAVINTA LLC. | 2008-05-29 | — | — | US | disclosed |
| US-4546186-A | 1,4,5,6,7,8-Hexahydro-2-methyl-5-oxo-4-(2-thiazolyl)-3-quinoline carboxylic acid 2-methyl(phenylmethyl)amino ethyl ester and pharmaceutically acceptable salts | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-10-08 | — | — | US | disclosed |
| EP-0059291-B1 | ANTIHYPERTENSIVE AGENTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1985-03-27 | — | — | EP | disclosed |
| EP-0128010-A2 | 1,4-Dihydropyridine derivative, process for production thereof and pharmaceutical use thereof | TEIJIN LIMITED (JP) | 1984-12-12 | — | — | EP | disclosed |
| EP-0114273-A1 | New pharmacologically active pyrazolopyridines | GRUPPO LEPETIT S.p.A. (IT) | 1984-08-01 | — | — | EP | disclosed |
| EP-0059291-A1 | Antihypertensive agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-09-08 | — | — | EP | disclosed |
| US-4321384-A | Antihypertensive agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1982-03-23 | — | — | US | disclosed |
| US-4248873-A | Nitro-substituted 1,4-dihydropyridines, processes for _their production and their medicinal use | BAYER AKTIENGESELLSCHAFT (DE) | 1981-02-03 | — | — | US | disclosed |
| US-4179500-A | 1,4-Dihydropyridine-sugar derivatives, and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-12-18 | — | — | US | disclosed |
| US-3985758-A | 1,4-Dihydropyridine derivatives | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JA) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125595-A1 | Single step one pot process for making nicardipine hydrochloride from 3-nitro-benzaldehyde, methyl aminocrotonate, and N-benzyl-N-methylaminoethyl acetoacetate; aqueous, injectable isotonic solution of nicardipine hydrochloride, L-arginine, and a sugar alcohol | ADH1C, PRMT1, SCN1B | SMN1; SMN2 376/4885ALDH1A1 426/4885TSHR 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.